Literature DB >> 7342692

Enprofylline, a principally new antiasthmatic xanthine.

C G Persson, G Kjellin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7342692     DOI: 10.1111/j.1600-0773.1981.tb00912.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


× No keyword cloud information.
  17 in total

1.  A comparison of the CNS effects of enprofylline and theophylline in healthy subjects assessed by performance testing and subjective measures.

Authors:  B Tiplady; D Fagan; M Lamont; M Brockway; D B Scott
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

2.  Creation of four consecutive instantaneous steady-state plasma concentration plateaus of theophylline and enprofylline by repeated infusions with exponentially decreasing delivery rates.

Authors:  J Kraan; L Borgström; G H Koëter; M Laseur; J H Jonkman; O E de Noord
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 3.  Asthma: 2. Trends in pharmacologic therapy.

Authors:  A S Rebuck; K R Chapman
Journal:  CMAJ       Date:  1987-03-01       Impact factor: 8.262

4.  The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease.

Authors:  J Kraan; J H Jonkman; G H Koëter; C H Gips; P E de Jong; T W van der Mark; I Ekman; R A de Zeeuw
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Inhibitory actions of enprofylline and aminophylline on extravasation of plasma proteins induced by various agents in the rat skin.

Authors:  G Thomas; J C Duarte
Journal:  Agents Actions       Date:  1984-12

6.  Protein binding of enprofylline.

Authors:  K Tegnér; O Borgå; I Svensson
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose.

Authors:  E Lunell; O Borgå; R Larsson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease.

Authors:  E Lunell; N Svedmyr; K E Andersson; C G Persson
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Maximally effective plasma concentrations of enprofylline and theophylline during constant infusion.

Authors:  L C Laursen; N Johannesson; I Søndergaard; B Weeke
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

10.  Comparison of oral enprofylline and theophylline in asthmatic patients.

Authors:  L C Laursen; N Johannesson; I Søndergaard; B Weeke
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.